Tensha Therapeutics, Inc. (extinct)

Co-Founder at C4 Therapeutics, Inc.

Healthcare Ventures (HCV) invests in pre-clinical or early clinical stage, project-focused companies with the potential to transform patient care. The firm seeks to identify high potential products within academia or pharmaceutical companies and develop them into clinical proof-of-concept within capital efficient, semi-virtual organizations. They seek to generate superior returns through acquisitions by pharmaceutical and biotechnology companies. HCV invests in early-stage and emerging growth healthcare companies that have the potential for exceptional growth. The firm invests primarily in privately-owned companies. They target companies that are well-positioned to grow rapidly in value based on product development timelines, capital requirements and future demand for products. The companies HCV invests in support a broad array of technology platforms and offer late-stage products or novel innovations. The firm also looks for companies that can retain their product rights and have near-term potential cash flow. HCV expects liquidity in 3 to 5 years at a valuation in excess of 10 times invested capital. Companies should have revenues that minimize equity capital requirements and technology platforms that generate multiple products.